In addition, we demonstrated that the therapeutic target of berberine was to inhibit the expression of FOXM1 and POLE2 mediated by FOXM1, so as to intervene the survival of lung adenocarcinoma (Overview of this study). The gene discussed is POLE2; the disease is lung adenocarcinoma.